Physician profile
Daniel B Kim
NPI 1538299771
$7,672.41
in general payments reported to CMS, 2019-2025
23 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $3,371 · 2021: $690 · 2022: $656 · 2023: $500 · 2024: $1,431 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543 · Gift: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,542.55 |
| Gift | $780.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apyx Medical Corporation | $3,221.94 | 2020 | |
| Mentor Worldwide LLC | $1,448.95 | 2020-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Sientra, INC. | $1,126.16 | 2019-2022 | |
| Abbvie INC. | $546.50 | 2023-2025 | |
| Allergan, INC. | $290.34 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.07 | 2023-2025 | Xifaxan |
| Galderma Laboratories, L.P. | $145.17 | 2019-2024 | |
| Integra Lifesciences Corporation | $96.47 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Celularity INC. | $76.00 | 2019 | |
| Baxter Healthcare | $71.01 | 2021-2023 | Artiss |
| Boston Scientific Corporation | $62.95 | 2025 | Wavewriter Alpha Prime 16 |
| Janssen Biotech, INC. | $59.47 | 2022-2024 | Tremfya |
| Avanos Medical | $56.51 | 2023-2024 | On-Q* Pump and Accessories |
| Revance Therapeutics, INC. | $50.86 | 2024 | Daxxify |
| Pacira Pharmaceuticals Incorporated | $44.58 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $43.40 | 2024 | Omvoh |
| Davol INC. | $31.64 | 2021 | |
| Astellas Pharma US INC | $27.97 | 2025 | Vyloy |
| Lucid Diagnostics INC. | $24.43 | 2022 | |
| Depuy Synthes Sales INC. | $22.72 | 2019 | |
| Alcresta Therapeutics, INC. | $22.04 | 2024 | Relizorb |
| Tela Bio, INC. | $14.62 | 2021 | |
| Medtronic USA, INC. | $14.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.